Triptorelin
Also known as: AY-25650, D-Trp6-LHRH, Decapeptyl, Diphereline, Gonapeptyl, Trelstar, Triptorelin acetate
Source Triptorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Triptorelin is a synthetic decapeptide GnRH agonist approved for prescription use. By suppressing the pituitary release of luteinising hormone and follicle‑stimulating hormone, it creates a hypo‑gonadal state that lowers circulating estrogen or testosterone. It is employed as part of ovarian suppression in premenopausal breast‑cancer patients, to achieve medical castration in advanced prostate cancer, and to induce hypo‑estrogenism for endometriosis symptom control.
Mechanism of Action
Triptorelin binds to GnRH receptors on pituitary gonadotropes, initially stimulating a transient surge of LH and FSH followed by receptor down‑regulation and desensitisation. The resulting decline in LH/FSH suppresses ovarian estrogen production in women and testicular testosterone production in men, producing a reversible medical menopause or castration that underlies its therapeutic effects.
What the Research Shows
A patient‑level meta‑analysis of four randomised trials (7030 premenopausal women) showed that, when ovarian suppression was achieved with triptorelin (or goserelin), aromatase inhibitors reduced breast‑cancer recurrence compared with tamoxifen (RR 0.79). In a pivotal non‑comparative multicentre study of 120 men with advanced prostate cancer, a 6‑month intramuscular depot of triptorelin embonate achieved castrate testosterone in >97% of patients within a month and maintained it through 12 months. Reviews of endometriosis treatment report that GnRH agonists, including triptorelin, relieve pelvic pain and improve pregnancy rates, though they are associated with a higher incidence of adverse events.
Reported Benefits
When used for ovarian suppression, triptorelin enables aromatase inhibitors to lower breast‑cancer recurrence in premenopausal women. In advanced prostate cancer, it reliably induces and sustains castrate testosterone levels, supporting disease control. In endometriosis, triptorelin reduces pain and may enhance fertility outcomes, as reflected in clinical reviews.
Limitations of the Evidence
The breast‑cancer benefit derives from trials where triptorelin was one of several ovarian‑suppression options, so its isolated effect is not quantified. Prostate‑cancer data come from a single, non‑comparative trial with a modest sample size. Endometriosis evidence consists mainly of narrative reviews and small studies; large, blinded RCTs are limited, and the long‑term impact on ovarian reserve remains uncertain.
Safety Considerations
Triptorelin induces hypo‑estrogenic or hypo‑testosterone states, leading to hot flushes, headache, and potential bone‑density loss; bone fractures were noted more frequently with aromatase inhibitors used alongside ovarian suppression. In the prostate‑cancer depot study, mild adverse events were common, with injection‑site reactions in 6.7% of patients. Clinicians should monitor bone health and manage menopausal‑type symptoms during treatment.
How It Is Administered
Triptorelin is administered by injection, either intramuscularly or subcutaneously. Formulations include monthly or 3‑month depots, and a 6‑month intramuscular depot delivering 22.5 mg. The drug is supplied as a sterile solution for use by healthcare professionals.
Routes of Administration
Goals & Uses
- Prostate cancerOncologyHigh
- Prostate cancer treatmentOncologyHigh
- Central precocious pubertyPediatric EndocrinologyHigh
- Uterine fibroid reductionGynecologyHigh
- Precocious pubertyPediatric EndocrinologyHigh
- Fertility preservation / controlled ovarian stimulationReproductive MedicineModerate
- Endometriosis managementGynecologyHigh
- Breast cancer (hormone‑sensitive)OncologyModerate
- EndometriosisGynecologyHigh
- Gender-affirming hormone therapyEndocrinologyModerate
- Assisted reproductionFertilityHigh
Contraindications
- Spinal cord compression or urinary obstructionUrological/neurologicalHigh
- Hypersensitivity to triptorelin or formulation excipientsImmunologicModerate
- Severe hepatic impairmentOrganModerateLiver function concerns
- Undiagnosed vaginal bleedingGynecologicalModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to GnRH, GnRH analogs, or triptorelinAllergyHigh
- BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
Adverse Effects
- Mood changes (depression, anxiety)PsychiatricUncommon
- Injection site reactionsLocalCommon
- Injection site painLocalCommonPain at the injection site
- Decreased bone mineral densityMusculoskeletalCommon
- Decreased libidoSexual / EndocrineCommon
- Hot flashesEndocrine / VasomotorCommon
- Bone mineral density lossSkeletalUncommon
- Erectile dysfunction / decreased libidoSexualCommon
- Hot flushes/flashesVasomotorCommon
- Testosterone flareEndocrineCommon
- Cardiovascular events (QT prolongation, metabolic syndrome)Cardiovascular/metabolicUncommon
Drug Interactions
- CYP3A4 inducers (e.g., rifampin)Low
- Antidiabetic agentsModerate
- Estrogen replacement therapyModerate
- Antiandrogens (e.g., bicalutamide)Low
- QT-prolonging agents (e.g., antiarrhythmics, antipsychotics)High
- Warfarin / anticoagulantsModerate
Population Constraints
- Elderly patients with cardiovascular diseaseCardiovascularRelative
- Pediatric patients (non-precocious puberty use)AgeRelative
- Pediatric patients (precocious puberty)AgeRelative
- Patients with diabetes mellitusMetabolicRelative
- Patients with osteoporosisMusculoskeletalRelative
- Pregnant womenReproductiveAbsolute
Regulatory Status
- European UnionApprovedApproved: prostate cancer, endometriosis, precocious puberty, assisted reproduction, breast cancerMultiple depot formulations.
- United StatesApprovedApproved: prostate cancer, endometriosis, precocious puberty, assisted reproductionMarketed as Trelstar.
- United KingdomApprovedApproved: prostate cancer, endometriosis, precocious puberty, assisted reproductionSame as EU.
Approved in the US, EU and UK in depot injection formulations (e.g., 1‑month, 3‑month, 6‑month). Marketed under several brand names.
Evidence & Sources
- Journal ArticleHighEarly Breast Cancer Trialists' Collaborative Group (EBCTCG)2022-01-01T00:00:00.000000Z
- Journal ArticleModerateKeating GM2010-01-01T00:00:00.000000Z
- Journal ArticleModerateBrown J, Farquhar C2015-01-01T00:00:00.000000Z
- Journal ArticleModerateLeone Roberti Maggiore U, et al.2014-01-01T00:00:00.000000Z
Frequently Asked Questions
How does triptorelin differ from other GnRH agonists?
All GnRH agonists act by down‑regulating pituitary GnRH receptors, but triptorelin is available in long‑acting depot formulations (e.g., 3‑month and 6‑month) that allow less frequent dosing, which can improve convenience in chronic conditions.
Can triptorelin be used alone for breast‑cancer treatment?
In premenopausal breast cancer, triptorelin is used to suppress ovarian estrogen production, allowing aromatase inhibitors to be effective; it is not used as a standalone endocrine therapy.
What are the main side effects patients should expect?
Common effects stem from reduced sex hormones: hot flushes, night sweats, mood changes, and mild injection‑site reactions. Bone‑density loss can occur with prolonged use, so monitoring and preventive measures are advised.
Is triptorelin reversible after stopping treatment?
Yes, the hypo‑gonadal state is reversible; menstrual cycles and testosterone production typically resume within weeks to months after the final injection, depending on the depot duration.
Is triptorelin safe for long‑term use?
Long‑term safety data are limited; while short‑term studies report mild adverse events, prolonged hypo‑estrogenism can increase risks of osteoporosis and cardiovascular changes, warranting periodic assessment.
What is Triptorelin?
Triptorelin is a synthetic decapeptide GnRH agonist approved for prescription use. By suppressing the pituitary release of luteinising hormone and follicle‑stimulating hormone, it creates a hypo‑gonadal state that lowers circulating estrogen or testosterone. It is employed as part of ovarian suppression in premenopausal breast‑cancer patients, to achieve medical castration in advanced prostate cancer, and to induce hypo‑estrogenism for endometriosis symptom control.
What is Triptorelin used for?
Triptorelin is educationally associated with: Prostate cancer, Prostate cancer treatment, Central precocious puberty, Uterine fibroid reduction, Precocious puberty, Fertility preservation / controlled ovarian stimulation, Endometriosis management, Breast cancer (hormone‑sensitive), Endometriosis, Gender-affirming hormone therapy, Assisted reproduction. Educational only — not medical advice.
How is Triptorelin administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of Triptorelin?
Reported adverse effects include: Mood changes (depression, anxiety), Injection site reactions, Injection site pain, Decreased bone mineral density, Decreased libido, Hot flashes, Bone mineral density loss, Erectile dysfunction / decreased libido, Hot flushes/flashes, Testosterone flare, Cardiovascular events (QT prolongation, metabolic syndrome). This list is not exhaustive — consult a qualified clinician.
Who should avoid Triptorelin?
Recorded contraindications: Spinal cord compression or urinary obstruction, Hypersensitivity to triptorelin or formulation excipients, Severe hepatic impairment, Undiagnosed vaginal bleeding, Pregnancy, Hypersensitivity to GnRH, GnRH analogs, or triptorelin, Breastfeeding. Consult a qualified clinician before use.